Using a large-scale, loss-of-function screening approach, our group previously identified the CT antigen, ZNF165, as essential for triple-negative breast cancer (TNBC) survival (Maxfield et al., 2015). This evidence concerns the gene ZNF165 and triple-negative breast carcinoma.